MOLOGEN : resolves first capital increase for the execution of the Share Subscription Facility concluded in October 2017

Insider information according to article 17 MAR

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

MOLOGEN AG resolves first capital increase for the execution of the Share Subscription Facility concluded in October 2017

Berlin, 18 December 2017 - The Executive Board of biopharmaceutical company MOLOGEN AG (ISIN DE0006637200, SIN 663720) today resolved, with the approval of the Supervisory Board, an increase of the share capital against contribution in cash without subscription rights for shareholders on the basis of the authorized capital. The Company's share capital is to be increased from currently EUR 34,295,343 to EUR 34,570,343 through issuing 275,000 new non-par value ordinary bearer shares. The new shares were privately placed with the US investor Global Corporate Finance (GCF) at a price of EUR 2.198 per new share within the framework of the Share Subscription Facility announced on 24 October 2017. The placement price equals 95% of the five consecutive trading days Volume Weighted Average Price (VWAP). Through this capital increase MOLOGEN will receive gross proceeds of EUR 604,450.

As announced in the ad-hoc notification on 24 October 2017, MOLOGEN intends to exercise its right towards the investor to issue draw-down notices within the upcoming months. Based on the current planning, MOLOGEN will implement several additional capital increases within the next months on a similar scale as the one resolved today - depending on the market conditions - until the Company has fully utilized the total volume of the Share Subscription Facility amounting to originally 3,394,725 shares (now 3,119,725). The new shares will each be placed at a price equal to 95% of the five consecutive trading days Volume Weighted Average Price (VWAP) following the relevant draw down notice. The scale of one draw down notice corresponds to the daily sales volume on certain trading platforms during the last five trading days before the declaration of the draw down notice multiplied by a factor. The total purchase price for the shares to be placed per draw-down-notice is limited to EUR 1,000,000. Based on these prospective capital increases, and based on the current share price, MOLOGEN could receive gross proceeds amounting to around EUR 8 million, depending on the further share price development. These proceeds would be used to finance the Company's operations beyond Q1 2018 and, in particular, for the further implementation of the strategy "Next level".

Important note:
This announcement is not an offer of securities for sale in the United States, Australia, Canada, Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to in this press release have not been, and will not be, registered under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offering of the securities in the United States of America. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada or Japan or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan.

Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

Note about risk for future predictions
Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.